QL1706 for advanced bone and soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of bone or soft tissue sarcoma that has spread or cannot be removed by surgery, including specific types like undifferentiated sarcoma, leiomyosarcoma, or chordoma.
- You must have had at least one prior standard chemotherapy (like doxorubicin or paclitaxel) for certain sarcoma types, unless you have a type like chordoma where no standard therapy exists.
- You must be willing to provide tumor tissue and blood samples for testing.
- You must be in generally good health with an ECOG performance status of 0 or 1 (able to carry out daily activities) and have adequate organ function (kidney, liver, blood, and heart).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This study tests an experimental drug called QLS5132 for people with advanced solid tumors (cancers that start in organs or tissues). The drug targets a protein called CLDN6 on some cancer cells and might help stop the tumor from growing.
This trial tests an experimental drug (QLS1209) for advanced solid tumors that have not responded to standard treatments or when no standard treatment exists. The study looks for tumors with certain genetic changes (in CCNE1, FBXW7, or PPP2R1A) and may help guide future treatment options.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
Hear when a new Bone and Soft Tissue Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.